LU91519I2 - "Doripenem et ses dérivés pharmaceutiquement acceptables - DORIBAXr" - Google Patents

"Doripenem et ses dérivés pharmaceutiquement acceptables - DORIBAXr"

Info

Publication number
LU91519I2
LU91519I2 LU91519C LU91519C LU91519I2 LU 91519 I2 LU91519 I2 LU 91519I2 LU 91519 C LU91519 C LU 91519C LU 91519 C LU91519 C LU 91519C LU 91519 I2 LU91519 I2 LU 91519I2
Authority
LU
Luxembourg
Prior art keywords
group
hydrogen
protecting group
doribaxr
doripenem
Prior art date
Application number
LU91519C
Other languages
English (en)
Original Assignee
Shionogi Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26374345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91519(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi Seiyaku Kk filed Critical Shionogi Seiyaku Kk
Publication of LU91519I2 publication Critical patent/LU91519I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/02—Preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/14—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L63/00—Compositions of epoxy resins; Compositions of derivatives of epoxy resins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LU91519C 1991-08-20 2009-01-23 "Doripenem et ses dérivés pharmaceutiquement acceptables - DORIBAXr" LU91519I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20797291 1991-08-20
JP3536692 1992-02-21

Publications (1)

Publication Number Publication Date
LU91519I2 true LU91519I2 (fr) 2009-03-23

Family

ID=26374345

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91519C LU91519I2 (fr) 1991-08-20 2009-01-23 "Doripenem et ses dérivés pharmaceutiquement acceptables - DORIBAXr"

Country Status (18)

Country Link
US (2) US5317016A (fr)
EP (1) EP0528678B1 (fr)
JP (1) JP2542773B2 (fr)
KR (1) KR100245671B1 (fr)
CN (2) CN1032257C (fr)
AT (1) ATE201413T1 (fr)
AU (1) AU652273B2 (fr)
CA (2) CA2076430C (fr)
DE (2) DE69231834T2 (fr)
DK (1) DK0528678T3 (fr)
ES (1) ES2159277T3 (fr)
GR (1) GR3036434T3 (fr)
LU (1) LU91519I2 (fr)
MX (1) MX9204805A (fr)
NL (1) NL300374I2 (fr)
NO (1) NO301371B1 (fr)
PT (1) PT528678E (fr)
TW (1) TW325475B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0611115B1 (fr) * 1993-02-10 2001-04-18 Shionogi & Co., Ltd. Préparation de dérivés de béta-lactame et intermédiaires
US5563264A (en) * 1993-02-10 1996-10-08 Shionogi & Co., Ltd. Preparation of βlactam compounds
US6111098A (en) * 1994-05-02 2000-08-29 Shionogi & Co., Ltd. Crystal of pyrrolidylthiocarbapenem derivative, lyophilized preparation containing said crystal, and process for producing the same
TW445265B (en) * 1996-11-25 2001-07-11 Meiji Seika Kaisha Carbapenem derivatives and antimicrobial agents
TW577875B (en) * 1997-01-31 2004-03-01 Shionogi & Co Pyrrolidine derivatives with inhibitory activity for phospholipase A2
US6750344B1 (en) 1997-09-05 2004-06-15 Isis Pharmaceuticals, Inc. Amine compounds and combinatorial libraries comprising same
EP1270575B1 (fr) * 2000-03-31 2005-09-07 Shionogi & Co., Ltd. Nouvelle forme cristalline d'un derive de pyrrolidylthiocarbapenem
CN100406439C (zh) * 2000-07-19 2008-07-30 霍夫曼-拉罗奇有限公司 作为金属蛋白酶抑制剂的吡咯烷衍生物
WO2002006271A1 (fr) * 2000-07-19 2002-01-24 F. Hoffmann-La Roche Ag Derives de pyrimidine
JP5328170B2 (ja) * 2001-05-10 2013-10-30 塩野義製薬株式会社 アセチルチオピロリジン誘導体の製法
JP5004355B2 (ja) * 2001-05-10 2012-08-22 塩野義製薬株式会社 アセチルチオピロリジン誘導体の製法
KR100473398B1 (ko) * 2002-08-31 2005-03-10 주식회사 하원제약 옥심기를 포함하는 피롤리딘 치환체를 가지는1-베타메틸카바페넴 유도체 및 그 제조방법
WO2004072073A1 (fr) * 2003-02-14 2004-08-26 Shionogi & Co., Ltd. Cristal de produit intermediaire pour carbapenem
US20050065141A1 (en) * 2003-07-31 2005-03-24 Odink Debra A. Carbapenems useful in treating and preventing pulmonary infections, pharmaceutical compositions thereof and modes of administration thereof
EP1797879A4 (fr) * 2004-10-08 2009-05-06 Dainippon Sumitomo Pharma Co Nouveau médicament anti-microbien
JP2008044847A (ja) * 2004-11-01 2008-02-28 Shionogi & Co Ltd カルバペネム合成体およびその製造法
US7932381B2 (en) * 2005-02-15 2011-04-26 Shionogi & Co., Ltd. Process for producing carbapenem derivative and intermediate crystal therefor
WO2006087996A1 (fr) * 2005-02-15 2006-08-24 Shionogi & Co., Ltd. Procede de production d'un derive de carbapeneme et d'un intermediaire cristallin de celui-ci
WO2006117763A2 (fr) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Procede de preparation de doripeneme
TWI353855B (en) 2005-05-26 2011-12-11 Shionogi & Co Method for preparing an aqueous solution of doripe
WO2007004028A2 (fr) * 2005-06-30 2007-01-11 Ranbaxy Laboratories Limited Procedes de preparation de penemes et de leurs intermediaires
CN100460389C (zh) * 2005-07-15 2009-02-11 成都地奥九泓制药厂 吡咯烷衍生物中间体及其制备方法和用途
JP2008303143A (ja) * 2005-08-19 2008-12-18 Shionogi & Co Ltd 連続化反応によるカルバぺネム誘導体の製法
DK1926732T3 (da) 2005-09-05 2013-12-09 Ranbaxy Lab Ltd Fremgangsmåde til fremstillingen af carbapenemforbindelser
CN100582106C (zh) * 2006-01-27 2010-01-20 上海医药工业研究院 一种吡咯烷硫基碳青霉烯衍生物的制备方法及其中间体
ES2355950T3 (es) * 2006-06-28 2011-04-01 Pfizer Products Inc. Profármacos de penem.
CN101333219B (zh) * 2007-06-26 2010-10-13 山东轩竹医药科技有限公司 含有巯基吡咯烷甲酰胺苯烷基杂环的培南衍生物
CN101362757A (zh) * 2007-08-09 2009-02-11 山东轩竹医药科技有限公司 磺酰基取代的碳青霉烯类化合物
US20090075969A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched doripenem
PL2276762T3 (pl) * 2008-03-24 2015-06-30 Ranbaxy Laboratories Ltd Sposób wytwarzania jałowego doripenemu
KR20110049823A (ko) * 2008-07-30 2011-05-12 랜박시 래보러터리스 리미티드 카르바페넴 화합물의 제조 방법
WO2011048583A1 (fr) 2009-10-23 2011-04-28 Ranbaxy Laboratories Limited Procédé pour la préparation de composés de carbapénème
CN102153553A (zh) * 2010-02-11 2011-08-17 山东轩竹医药科技有限公司 含有氨基磺酰胺基氮杂环丁烷的口服碳青霉烯化合物
CN102249970A (zh) * 2011-05-09 2011-11-23 黄山市歙县宏辉化工有限公司 一种多尼培南侧链的合成工艺
EP2776440A1 (fr) 2011-11-08 2014-09-17 Ranbaxy Laboratories Limited Procédé de préparation de polymorphes de doripénème
CN102702201B (zh) * 2012-03-26 2013-12-25 深圳市海滨制药有限公司 一种多尼培南中间体化合物、其制备方法和用途以及多尼培南的制备方法
CN102964286B (zh) * 2012-12-06 2014-06-25 石家庄万尚医药科技有限公司 一种手性吡咯烷化合物及其制备方法
US11067210B2 (en) * 2013-03-15 2021-07-20 Colder Products Company Low-spill coupling assembly
CN104496993B (zh) * 2014-09-18 2017-04-05 山东省生物医药科学院 一种碳青霉烯酯衍生物
KR20160007679A (ko) 2016-01-04 2016-01-20 제일약품주식회사 도리페넴의 신규한 결정형
US10695322B2 (en) 2016-01-29 2020-06-30 The Johns Hopkins University Inhibitors of bacterial growth
JP7213173B2 (ja) 2016-03-16 2023-01-26 オーキッド ファーマ リミテッド カルバペネム化合物
KR20220084398A (ko) * 2019-11-22 2022-06-21 쑤저우 얼예 파마슈티칼 컴퍼니 리미티드 설포닐우레아 고리 치환 모노시클릭 β-락탐계 항생제
CN111960984B (zh) * 2020-09-11 2023-04-28 江西如益科技发展有限公司 一种合成多尼培南侧链中间体的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260543A (en) * 1978-07-03 1981-04-07 Merck & Co., Inc. Crystalline N-formimidoyl thienamycin
DK153486C (da) * 1978-07-03 1988-11-28 Merck & Co Inc Analogifremgangsmaade til fremstilling af krystallinsk n-formimidoyl-thienamycin-monohydrat
JPS60233076A (ja) * 1984-05-03 1985-11-19 Sumitomo Chem Co Ltd 新規なβ−ラクタム化合物およびその製造法
EP0182213B1 (fr) * 1984-11-08 1990-09-26 Sumitomo Pharmaceuticals Company, Limited Dérivés de carbapénème et leur préparatIon
JPS62155279A (ja) * 1984-11-08 1987-07-10 Sumitomo Pharmaceut Co Ltd 新規なβ−ラクタム化合物
KR880006244A (ko) * 1986-11-24 1988-07-22 후지사와 도모 기찌 로 3-피롤리디닐티오-1-아자바이스클로[3.2.0]햅트2-엔-2-카르복실산 화합물 및 이의 제조방법
WO1990011284A1 (fr) * 1989-03-28 1990-10-04 Pfizer Inc. Derives de 2-carbapenem antibacteriens
US5157125A (en) * 1989-09-25 1992-10-20 Pfizer Inc. Optically active 2-alkyl-2,5-diazabicyclo[2.2.1]heptanes
FI96311C (fi) * 1989-12-04 1996-06-10 Squibb Bristol Myers Co Menetelmä farmaseuttisesti käyttökelpoisten 6-(1-hydroksietyyli)-3-(substituoitu tio)-7-okso-1-atsabisyklo/3.2.0/hept-2-eeni-2-karboksyylihappojohdannaisten valmistamiseksi
IL99513A0 (en) * 1990-09-20 1992-08-18 Hoechst Ag Process for the preparation of carbapenem compounds
TW209220B (fr) * 1991-11-27 1993-07-11 Manyu Seiyaku Kk

Also Published As

Publication number Publication date
DK0528678T3 (da) 2001-07-30
EP0528678A1 (fr) 1993-02-24
CA2076430A1 (fr) 1993-02-21
JPH05294970A (ja) 1993-11-09
CN1032257C (zh) 1996-07-10
TW325475B (en) 1998-01-21
DE122009000002I1 (de) 2009-05-20
NO301371B1 (no) 1997-10-20
CA2076430C (fr) 1997-12-23
CA2203942C (fr) 2001-02-13
NL300374I2 (nl) 2009-06-02
NO923256D0 (no) 1992-08-19
CA2203942A1 (fr) 1993-02-21
KR100245671B1 (ko) 2000-05-01
CN1071428A (zh) 1993-04-28
CN1034571C (zh) 1997-04-16
AU2109092A (en) 1993-02-25
JP2542773B2 (ja) 1996-10-09
AU652273B2 (en) 1994-08-18
ES2159277T3 (es) 2001-10-01
MX9204805A (es) 1993-05-01
PT528678E (pt) 2001-08-30
KR930004306A (ko) 1993-03-22
GR3036434T3 (en) 2001-11-30
EP0528678B1 (fr) 2001-05-23
DE69231834T2 (de) 2002-03-28
NO923256L (no) 1993-02-22
US5317016A (en) 1994-05-31
US5703243A (en) 1997-12-30
CN1113233A (zh) 1995-12-13
NL300374I1 (nl) 2009-04-01
ATE201413T1 (de) 2001-06-15
DE69231834D1 (de) 2001-06-28

Similar Documents

Publication Publication Date Title
LU91519I2 (fr) "Doripenem et ses dérivés pharmaceutiquement acceptables - DORIBAXr"
KR100202474B1 (en) Novel tetrapeptide derivative
DE69231661D1 (de) Antifungizide trisubstituierte tetrahydrofurane
HK1011967A1 (en) Amide derivatives having anti-hyper cholesteremic activity their preparation and their therapeutic uses
IL94027A0 (en) Diaminoethylene compounds
HU9503090D0 (en) Novel bisoxadiazolidine derivative
DE68913835D1 (de) N-substituierte Amid-Derivate.
EP0601191A4 (en) Novel tetracyclic compound.
EP1043319A4 (fr) Nouveaux derives alkylamino
GR3031767T3 (en) Cyclopropane derivatives and antiviral agents containing the same.
AU3386093A (en) Tetrahydrothiophene derivatives
DK0565059T3 (da) Indolderivat
TW216417B (en) Carboxylic acid derivative having retinoid type pharmacological activities